1. Home
  2. NATR vs CBIO Comparison

NATR vs CBIO Comparison

Compare NATR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NATR
  • CBIO
  • Stock Information
  • Founded
  • NATR 1972
  • CBIO 2003
  • Country
  • NATR United States
  • CBIO United States
  • Employees
  • NATR N/A
  • CBIO N/A
  • Industry
  • NATR Biotechnology: Pharmaceutical Preparations
  • CBIO
  • Sector
  • NATR Health Care
  • CBIO
  • Exchange
  • NATR Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • NATR 237.7M
  • CBIO 209.8M
  • IPO Year
  • NATR N/A
  • CBIO N/A
  • Fundamental
  • Price
  • NATR $13.75
  • CBIO $12.44
  • Analyst Decision
  • NATR Strong Buy
  • CBIO Strong Buy
  • Analyst Count
  • NATR 2
  • CBIO 5
  • Target Price
  • NATR $20.50
  • CBIO $25.60
  • AVG Volume (30 Days)
  • NATR 66.3K
  • CBIO 105.5K
  • Earning Date
  • NATR 11-06-2025
  • CBIO 11-23-2025
  • Dividend Yield
  • NATR N/A
  • CBIO N/A
  • EPS Growth
  • NATR N/A
  • CBIO N/A
  • EPS
  • NATR 0.75
  • CBIO N/A
  • Revenue
  • NATR $460,818,000.00
  • CBIO N/A
  • Revenue This Year
  • NATR $4.88
  • CBIO N/A
  • Revenue Next Year
  • NATR $2.66
  • CBIO N/A
  • P/E Ratio
  • NATR $18.37
  • CBIO N/A
  • Revenue Growth
  • NATR 4.33
  • CBIO N/A
  • 52 Week Low
  • NATR $11.01
  • CBIO $9.81
  • 52 Week High
  • NATR $18.06
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • NATR 37.57
  • CBIO 50.54
  • Support Level
  • NATR $12.97
  • CBIO $12.00
  • Resistance Level
  • NATR $13.99
  • CBIO $12.84
  • Average True Range (ATR)
  • NATR 0.42
  • CBIO 0.66
  • MACD
  • NATR 0.01
  • CBIO 0.05
  • Stochastic Oscillator
  • NATR 42.30
  • CBIO 58.50

About NATR Nature's Sunshine Products Inc.

Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: